Matches in SemOpenAlex for { <https://semopenalex.org/work/W4304080455> ?p ?o ?g. }
- W4304080455 endingPage "2091" @default.
- W4304080455 startingPage "2083" @default.
- W4304080455 abstract "The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes. The co-primary endpoints were the percentage change in body weight and achievement of weight loss of ≥5% at week 104. Efficacy was assessed among all randomized participants regardless of treatment discontinuation or rescue intervention. From 5 October 2018 to 1 February 2019, 304 participants were randomly assigned to semaglutide 2.4 mg (n = 152) or placebo (n = 152), 92.8% of whom completed the trial (attended the end-of-trial safety visit). Most participants were female (236 (77.6%)) and white (283 (93.1%)), with a mean (s.d.) age of 47.3 (11.0) years, body mass index of 38.5 (6.9) kg m-2 and weight of 106.0 (22.0) kg. The mean change in body weight from baseline to week 104 was -15.2% in the semaglutide group (n = 152) versus -2.6% with placebo (n = 152), for an estimated treatment difference of -12.6 %-points (95% confidence interval, -15.3 to -9.8; P < 0.0001). More participants in the semaglutide group than in the placebo group achieved weight loss ≥5% from baseline at week 104 (77.1% versus 34.4%; P < 0.0001). Gastrointestinal adverse events, mostly mild-to-moderate, were reported more often with semaglutide than with placebo (82.2% versus 53.9%). In summary, in adults with overweight (with at least one weight-related comorbidity) or obesity, semaglutide treatment led to substantial, sustained weight loss over 104 weeks versus placebo. NCT03693430." @default.
- W4304080455 created "2022-10-10" @default.
- W4304080455 creator A5003160509 @default.
- W4304080455 creator A5020292142 @default.
- W4304080455 creator A5026596594 @default.
- W4304080455 creator A5027441223 @default.
- W4304080455 creator A5038221659 @default.
- W4304080455 creator A5049042396 @default.
- W4304080455 creator A5052679600 @default.
- W4304080455 creator A5081590711 @default.
- W4304080455 creator A5085481226 @default.
- W4304080455 creator A5086072427 @default.
- W4304080455 creator A5088506788 @default.
- W4304080455 date "2022-10-01" @default.
- W4304080455 modified "2023-10-17" @default.
- W4304080455 title "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial" @default.
- W4304080455 cites W1922359108 @default.
- W4304080455 cites W1994320162 @default.
- W4304080455 cites W2001588817 @default.
- W4304080455 cites W2052518513 @default.
- W4304080455 cites W2119300162 @default.
- W4304080455 cites W2124477479 @default.
- W4304080455 cites W2130766522 @default.
- W4304080455 cites W2134860420 @default.
- W4304080455 cites W2140477129 @default.
- W4304080455 cites W2144948858 @default.
- W4304080455 cites W2148287957 @default.
- W4304080455 cites W2157135485 @default.
- W4304080455 cites W2467227824 @default.
- W4304080455 cites W2590664415 @default.
- W4304080455 cites W2612234120 @default.
- W4304080455 cites W2746751342 @default.
- W4304080455 cites W3028216699 @default.
- W4304080455 cites W3093042356 @default.
- W4304080455 cites W3121599370 @default.
- W4304080455 cites W3127371223 @default.
- W4304080455 cites W3129305070 @default.
- W4304080455 cites W3133746780 @default.
- W4304080455 cites W3138431202 @default.
- W4304080455 cites W4207005829 @default.
- W4304080455 cites W4212929213 @default.
- W4304080455 cites W4224218205 @default.
- W4304080455 cites W4283161220 @default.
- W4304080455 doi "https://doi.org/10.1038/s41591-022-02026-4" @default.
- W4304080455 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36216945" @default.
- W4304080455 hasPublicationYear "2022" @default.
- W4304080455 type Work @default.
- W4304080455 citedByCount "77" @default.
- W4304080455 countsByYear W43040804552022 @default.
- W4304080455 countsByYear W43040804552023 @default.
- W4304080455 crossrefType "journal-article" @default.
- W4304080455 hasAuthorship W4304080455A5003160509 @default.
- W4304080455 hasAuthorship W4304080455A5020292142 @default.
- W4304080455 hasAuthorship W4304080455A5026596594 @default.
- W4304080455 hasAuthorship W4304080455A5027441223 @default.
- W4304080455 hasAuthorship W4304080455A5038221659 @default.
- W4304080455 hasAuthorship W4304080455A5049042396 @default.
- W4304080455 hasAuthorship W4304080455A5052679600 @default.
- W4304080455 hasAuthorship W4304080455A5081590711 @default.
- W4304080455 hasAuthorship W4304080455A5085481226 @default.
- W4304080455 hasAuthorship W4304080455A5086072427 @default.
- W4304080455 hasAuthorship W4304080455A5088506788 @default.
- W4304080455 hasBestOaLocation W43040804551 @default.
- W4304080455 hasConcept C126322002 @default.
- W4304080455 hasConcept C134018914 @default.
- W4304080455 hasConcept C142724271 @default.
- W4304080455 hasConcept C168563851 @default.
- W4304080455 hasConcept C1862650 @default.
- W4304080455 hasConcept C197934379 @default.
- W4304080455 hasConcept C204787440 @default.
- W4304080455 hasConcept C27081682 @default.
- W4304080455 hasConcept C2777180221 @default.
- W4304080455 hasConcept C2778715236 @default.
- W4304080455 hasConcept C2780221984 @default.
- W4304080455 hasConcept C2780586474 @default.
- W4304080455 hasConcept C2781308992 @default.
- W4304080455 hasConcept C2909862629 @default.
- W4304080455 hasConcept C44249647 @default.
- W4304080455 hasConcept C511355011 @default.
- W4304080455 hasConcept C544821477 @default.
- W4304080455 hasConcept C555293320 @default.
- W4304080455 hasConcept C71924100 @default.
- W4304080455 hasConceptScore W4304080455C126322002 @default.
- W4304080455 hasConceptScore W4304080455C134018914 @default.
- W4304080455 hasConceptScore W4304080455C142724271 @default.
- W4304080455 hasConceptScore W4304080455C168563851 @default.
- W4304080455 hasConceptScore W4304080455C1862650 @default.
- W4304080455 hasConceptScore W4304080455C197934379 @default.
- W4304080455 hasConceptScore W4304080455C204787440 @default.
- W4304080455 hasConceptScore W4304080455C27081682 @default.
- W4304080455 hasConceptScore W4304080455C2777180221 @default.
- W4304080455 hasConceptScore W4304080455C2778715236 @default.
- W4304080455 hasConceptScore W4304080455C2780221984 @default.
- W4304080455 hasConceptScore W4304080455C2780586474 @default.
- W4304080455 hasConceptScore W4304080455C2781308992 @default.
- W4304080455 hasConceptScore W4304080455C2909862629 @default.
- W4304080455 hasConceptScore W4304080455C44249647 @default.
- W4304080455 hasConceptScore W4304080455C511355011 @default.